Prostate Cancer Clinical Trials in Scottsdale, Arizona

6 studies are recruiting for prostate cancer in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

   To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic, Scottsdale, Arizona

   Locations

   23 in total

   Run by

   Axonics, Inc.

   See if you can join NCT06511141 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health, Scottsdale, Arizona

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Scottsdale, Arizona

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

4. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

   The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as …

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Mayo Clinic Arizona, Scottsdale, Arizona

   Locations

   54 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT05803941 on ClinicalTrials.gov

5. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

6. Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

   The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic, Scottsdale, Arizona

   Locations

   4 in total

   Run by

   Proton Collaborative Group

   See if you can join NCT01492972 on ClinicalTrials.gov